29 January 2026
Takeda Q3 FY2025 Results: VYVANSE® Generics Impact, Cost Management, and Upcoming Launches
Revenue and core profit declined, but operating profit rose. New drug applications submitted, with launches expected in 18 months, aiming for long-term growth.